Clinical trials sponsored by Icahn School of Medicine at Mount Sinai
48
Recruiting trials
15
Conditions studied
Phase breakdown
Phase 1 4Phase 2 10Phase 3 2Phase 4 3Not applicable 31
Conditions studied
Recruiting trials led by Icahn School of Medicine at Mount Sinai
- A Study of the MIND Diet for Persons With Multiple Sclerosis
- Alnuctamab for Refractory SLE (LATTE Study)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- Antiviral Clinical Trial for Long Covid-19
- Assessment of Music Experiences in Navigating Depression Part 2
- Asthma Symptom Perception Study
- Behavioral Therapy for Crohn's Disease
- Biologics And Clinical Immunology Cohort at Sinai
- Cannabidiol in Sickle Cell Disease
- Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
- Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
- Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management
- Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
- Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
- Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation
- Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen
- Group-Care for Hypertension and Diabetes Management in Nepal
- High Fructose Diet, the Gut Microbiome, and Metabolic Health
- Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations
- Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients
- Kidney Precision Medicine Project
- Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
- Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
- Neural Circuit Effects of Ketamine in Depression
- Neutralizing Interleukin (IL)-6
- Pancreas Registry and High Risk Registry
- Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients
- Point of Care STI Testing
- Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
- Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
- SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
- Safety and Feasibility of DBS for Bipolar Depression
- Screening Women With Prior HPV for Anal Neoplasia
- SeizEAR Safety Study
- Social Isolation and Aging in Schizophrenia
- Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
- The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV Infection
- Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
- Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
- Upright MRI for Prostate Cancer Screening
- Use of ReDS Technology in Patients With Acute Heart Failure
- Vancomycin Study in Multiple Sclerosis (MS)
- Vestibular Innovation in Pain 2
- Virtual Reality (VR) Self-Hypnosis Software
- Virtual Reality for Pain Control in US-Guided Obstetric Needle Procedures
Common questions
How many trials is Icahn School of Medicine at Mount Sinai recruiting for?
Icahn School of Medicine at Mount Sinai is the lead sponsor of 48 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.